Welcome to our dedicated page for Dare Bioscience news (Ticker: DARE), a resource for investors and traders seeking the latest updates and insights on Dare Bioscience stock.
Daré Bioscience, Inc. develops and commercializes women’s health therapies across contraception, fertility, vaginal health, and sexual health. Its updates center on XACIATO, DARE to PLAY™ Sildenafil Cream, and investigational programs such as DARE-HPV and DARE-PTB1, an intravaginal ring program for prevention of preterm birth.
Recurring news themes include financial results, company updates, product availability through prescription and 503B channels, FDA and IND-related development milestones, clinical-program disclosures, and non-dilutive funding from government sources. Coverage also reflects Daré’s public reporting on product candidates, trials, financing, and business development.
Daré Bioscience (NASDAQ: DARE) launched its “Across the U.S.” Virtual Bus Tour Webinar Series, a multi-event investor engagement program hosted by President and CEO Sabrina Martucci Johnson. The live webcasts will provide corporate updates, commercial strategy insights, portfolio discussions, growth opportunities and interactive Q&A sessions.
The series will also cover Daré’s ongoing Regulation A offering and participation details. Scheduled “stops” include West Coast (July 23, 9:00 AM PT), Southern (August 5, 8:00 AM MT), Midwest (August 11, 11:30 AM CT) and East Coast (August 26, 3:30 PM ET). Replays will be available on the company’s investor website for 90 days.
Daré Bioscience (NASDAQ:DARE) announced that CEO Sabrina Martucci Johnson will participate in a Virtual Investor Closing Bell event on July 14, 2026, at 4:00 PM ET.
The live webcast and 90-day replay will be available on the company’s investor relations website.
Daré Bioscience (NASDAQ: DARE) launched Flora Sync LF5™, a non-hormonal vaginal probiotic capsule now sold direct-to-consumer via the DARE Health Hub, creating its first consumer product revenue stream. The product uses a vagina-specific Limosilactobacillus fermentum LF5 strain and costs $49 per 6-capsule box.
In a single-blind randomized trial of 100 women, 96% achieved vaginal microbiome balance within 3 days and 90% maintained balance at 2 weeks. Daré also highlighted upcoming DARE to PLAY™ Sildenafil Cream dispensing, a $10 million ARPA-H–funded Phase 2 study of DARE-HPV with topline data expected in 2027, and positive interim Phase 3 Ovaprene® results with DSMB support to continue.
Daré Bioscience (NASDAQ:DARE) discussed the upcoming June 2026 commercial launch of Flora Sync LF5™, a vagina-specific probiotic capsule designed to help restore microbiome balance and support vaginal comfort. The Virtual Investor “What This Means” segment highlighted its role as Daré’s first consumer health product and a potential source of direct product revenue within its broader women’s health strategy.
Daré Bioscience (NASDAQ:DARE) announced that President and CEO Sabrina Martucci Johnson will speak at multiple events and deliver a corporate presentation during the BIO International Convention 2026 in San Diego from June 22-25.
Sessions will cover women's health innovation, leadership, mentorship, and clinical development pathways.
Daré Bioscience (NASDAQ: DARE) announced the upcoming U.S. launch of Flora Sync LF5™, a vagina-specific probiotic capsule designed to restore microbiome balance and support vaginal comfort.
The company expects to generate its first direct consumer product revenue in June 2026, signaling a move from a pure development-stage biotech to a revenue-generating women's health company.
Daré Bioscience (NASDAQ:DARE) received a Notice of Award from NIAID for the second $1.0 million tranche of its SBIR grant, bringing total NIH funding for DARE-HPV to $2.0 million.
The non-dilutive funding supports non-clinical and translational work alongside a Phase 2 trial in about 100 women with persistent high-risk HPV infection, with topline data expected in 2027.
Daré Bioscience (NASDAQ:DARE) initiated a Phase 2 randomized, double-blind, placebo-controlled study of DARE-HPV, a vaginal insert containing lopinavir/ritonavir for persistent high-risk HPV infection, which currently has no FDA-approved pharmacologic treatments. The ARPA-H–funded $10 million program expects topline data in 2027.
Daré Bioscience (NASDAQ:DARE) reported Q1 2026 results and outlined upcoming commercial and clinical milestones. First direct product revenue is expected in June 2026 from U.S. launch of Flora Sync LF5, a vaginal probiotic distributed via the DARE Health Hub.
Key programs include DARE to PLAY sildenafil cream (dispensing targeted summer 2026), DARE to RECLAIM hormone therapy (revenue targeted 2027), a Phase 3 trial of Ovaprene with a second positive DSMB review, and DARE-HPV, advancing to Phase 2 with a $10 million ARPA-H contract.
Daré Bioscience (NASDAQ: DARE) reported positive interim Phase 3 results for Ovaprene, a novel hormone-free, monthly intravaginal contraceptive. A second independent DSMB review of safety data recommended the trial continue without modification.
Interim data from 339 women (1,789 cycles) showed an approximately 9% pregnancy rate, consistent with expectations, no serious device-related adverse events, and no increase or new types of adverse events with prolonged use. About 12% discontinued due to vaginal odor, a 5% decrease versus July 2025 data, and a majority of completers were likely to use Ovaprene if available. The single-arm, open-label Phase 3 study targets at least 2,500 exposure cycles in 2026, with the Pearl Index over 13 cycles as the primary endpoint.